Moderna stock, once soaring near $497 during the pandemic, now trades around $55.12 but shows a historically bullish trendline signal that has preceded an 82% chance of gains averaging 68% over the next month. Despite a recent 35% pullback from a July high of $85.60, the stock faces significant short interest at 14.3% of its float, which could trigger a short squeeze. Analyst upgrades are overdue, as most brokers rate it as "hold" or worse with price targets near current levels. Options traders remain bearish, reflected in a high put/call ratio, adding complexity to the outlook but also potential for a bullish reversal if bearish bets unwind.
ResearchAndMarkets.com released a comprehensive report covering over 1,350 precision medicine collaboration and licensing deals from 2019 to 2026. The report offers detailed insights into deal structures, financial terms, and partnership strategies, ...
The global influenza vaccine market, valued at $8.96 billion in 2024, is projected to reach $13.32 billion by 2030 with a 7% annual growth rate. Growth is fueled by rising public health awareness, an expanding elderly population, government immunizat...
The U.S. FDA has approved Moderna's mRNA-based flu vaccine, mFLUSIVA, for adults aged 50 and older, marking the first mRNA flu shot authorized in the country. Clinical trials showed it to be 26.6% more effective than traditional flu vaccines. The vac...
